Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2476 participants.

Also called NCT03417388

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,476 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03417388
Other papers using this trial's data
  • Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR): a randomised controlled trial Open heart, 2026-04-03 DOI, PubMed 41932694, PMC13052788 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03417388. Randomized; single masking; primary purpose treatment. Start 2018-02-09 (actual); primary completion 2025-02-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Acronym
WARRIOR
Intervention (Drug)
High dose potent statin
Intervention (Drug)
ACE-I (lisinopril) or ARB (losartan)
Intervention (Drug)
Aspirin 81 enteric coated tablet daily
Intervention (Behavioral)
Lifestyle Counseling
Intervention (Behavioral)
Quality of Life Questionnaires
Lead sponsor
Cedars-Sinai Medical Center (class: other)
Collaborator
United States Department of Defense (class: US federal agency)
Collaborator
University of Florida (class: other)

Record details

Record id
cardio:ct-nct03417388
Content hash
deafbe2ae4072bebaf781a8a134152b72b0abb5794493de92616cf5658c54351